$ELTX
Elicio Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000160148524000045 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $7.208M $8.180M
YoY Change -0.77% 65.45%
% of Gross Profit
Depreciation & Amortization $0.00 $80.00K
YoY Change -57.89%
% of Gross Profit
Operating Expenses $7.208M $8.180M
YoY Change -0.77% 65.45%
Operating Profit -$10.34M -$10.92M
YoY Change -3.96% 40.47%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$8.494M $3.695M
YoY Change -7616.81% 1594.95%
Pretax Income
YoY Change
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$18.84M -$7.229M
YoY Change 76.75% -4.37%
Net Earnings / Revenue
Basic Earnings Per Share -$1.39 -$0.64
Diluted Earnings Per Share -$1.39 -$0.64
COMMON SHARES
Basic Shares Outstanding 10.77M shares 10.27M shares
Diluted Shares Outstanding 13.58M shares 11.28M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.02M $3.425M
YoY Change 75.78% -84.22%
Cash & Equivalents $26.00M $3.400M
Short-Term Investments
Other Short-Term Assets $4.628M $2.922M
YoY Change -7.44% -26.95%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $30.65M $6.689M
YoY Change 53.76% -74.49%
LONG-TERM ASSETS
Property, Plant & Equipment $523.0K $597.0K
YoY Change -32.25% -35.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.293M $2.322M
YoY Change -63.06% -33.66%
Total Long-Term Assets $7.742M $9.061M
YoY Change -29.97% -20.48%
TOTAL ASSETS
Total Short-Term Assets $30.65M $6.689M
Total Long-Term Assets $7.742M $9.061M
Total Assets $38.39M $15.75M
YoY Change 23.88% -58.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.984M $1.055M
YoY Change -54.97% -75.26%
Accrued Expenses $4.852M $5.321M
YoY Change 9.87% 129.85%
Deferred Revenue $1.307M $400.0K
YoY Change -21.45%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.020M $7.585M
YoY Change -21.47% -0.16%
LONG-TERM LIABILITIES
Long-Term Debt $19.84M $0.00
YoY Change
Other Long-Term Liabilities $28.52M $9.817M
YoY Change 359.98% 51.03%
Total Long-Term Liabilities $48.35M $9.817M
YoY Change 679.9% 51.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.020M $7.585M
Total Long-Term Liabilities $48.35M $9.817M
Total Liabilities $57.37M $17.40M
YoY Change 224.13% 23.75%
SHAREHOLDERS EQUITY
Retained Earnings -$180.1M -$161.3M
YoY Change 35.11% 31.57%
Common Stock $108.0K $103.0K
YoY Change 28.57% 22.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$18.99M -$1.652M
YoY Change
Total Liabilities & Shareholders Equity $38.39M $15.75M
YoY Change 23.88% -58.13%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$18.84M -$7.229M
YoY Change 76.75% -4.37%
Depreciation, Depletion And Amortization $0.00 $80.00K
YoY Change -57.89%
Cash From Operating Activities -$7.274M -$8.928M
YoY Change 40.15% -6.32%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $42.00K
YoY Change -100.0% 110.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$42.00K
YoY Change -100.0% -100.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.75M 316.0K
YoY Change 51156.67% -99.09%
NET CHANGE
Cash From Operating Activities -7.274M -8.928M
Cash From Investing Activities 0.000 -42.00K
Cash From Financing Activities 30.75M 316.0K
Net Change In Cash 23.48M -8.654M
YoY Change -554.16% -124.52%
FREE CASH FLOW
Cash From Operating Activities -$7.274M -$8.928M
Capital Expenditures $0.00 $42.00K
Free Cash Flow -$7.274M -$8.970M
YoY Change 38.82% -6.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10273328 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9603723 shares
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10924000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7777000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
17402000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
15773000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Net Income Loss
NetIncomeLoss
-15586000 usd
us-gaap Depreciation
Depreciation
214000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
397000 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
429000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
23000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
503000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
604000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
136000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1201000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3314000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-344000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-498000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39000 usd
us-gaap Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
0 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14301000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7197000 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.65
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9618178 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10258873 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
103000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
96000 usd
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
14455 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
14455 shares
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
150000 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
150000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
159892000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
153827000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-238000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-197000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-161259000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-142203000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1652000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11373000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15750000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27146000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8180000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4944000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11827000 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2744000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2833000 usd
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
10924000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
7777000 usd
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3616000 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
23000 usd
CY2024Q2 angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
0 usd
CY2023Q2 angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
0 usd
CY2024Q2 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
CY2023Q2 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
321000 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
429000 usd
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
604000 usd
CY2024Q2 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
CY2023Q2 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
137000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
39000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
49000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
714000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3695000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
218000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7229000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7559000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
32000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7561000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.65
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11284853 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11284853 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10779389 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10779389 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1615772 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1615772 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11373000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
103000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5062000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
11000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
324000 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-73000 usd
CY2024Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
4870000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
9000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
303000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
350000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
32000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7229000 usd
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1652000 usd
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4997920 shares
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
111060000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-102145000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
34000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
224000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8029000 usd
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4997920 shares
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
111060000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-109876000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
11000 usd
CY2023Q2 angn Temporary Equity Stock Issued During Period Shares New Issues
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
4997920 shares
CY2023Q2 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
111060000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2400000 usd
CY2023Q2 angn Stock Issued During Period Value Reverse Recapitalization
StockIssuedDuringPeriodValueReverseRecapitalization
19739000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
150000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
279000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7559000 usd
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23557000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19056000 usd
us-gaap Depreciation
Depreciation
162000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
421000 usd
angn Interest Expense Noncash
InterestExpenseNoncash
0 usd
angn Interest Expense Noncash
InterestExpenseNoncash
1061000 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2338000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
674000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
-578000 usd
angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1083000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
8000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-79000 usd
angn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
1603000 usd
angn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-251000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1436000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-337000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21050000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17614000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
34000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13000 usd
us-gaap Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
24001000 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
2366000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
5962000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5365000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0 usd
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
150000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
67000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11340000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31552000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-41000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9790000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13949000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8414000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4511000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22363000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3425000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21682000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1086000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
681000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4511000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22363000 usd
angn Fair Value Of Common Stock Warrants
FairValueOfCommonStockWarrants
6579000 usd
angn Fair Value Of Common Stock Warrants
FairValueOfCommonStockWarrants
0 usd
angn Accretion Of Promissory Note Discount From Embedded Derivative
AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative
0 usd
angn Accretion Of Promissory Note Discount From Embedded Derivative
AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative
130000 usd
angn Accretion Of Promissory Note To Face Value
AccretionOfPromissoryNoteToFaceValue
0 usd
angn Accretion Of Promissory Note To Face Value
AccretionOfPromissoryNoteToFaceValue
897000 usd
angn Non Cash Vesting Of Restricted Common Stock
NonCashVestingOfRestrictedCommonStock
20000 usd
angn Non Cash Vesting Of Restricted Common Stock
NonCashVestingOfRestrictedCommonStock
45000 usd
angn Settlement Of Promissory Notes Payable
SettlementOfPromissoryNotesPayable
0 usd
angn Settlement Of Promissory Notes Payable
SettlementOfPromissoryNotesPayable
10028000 usd
angn Interest Expense From Promissory Notes Payable
InterestExpenseFromPromissoryNotesPayable
0 usd
angn Interest Expense From Promissory Notes Payable
InterestExpenseFromPromissoryNotesPayable
34000 usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9700000 shares
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-161300000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3400000 usd
CY2023Q2 angn Recapitalization Exchange Ratio
RecapitalizationExchangeRatio
0.0181
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Financial Statement Reclassification</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain account balances from prior periods have been reclassified in these condensed consolidated financial statements to conform to current period classifications. The warrant liability was reclassified from current to noncurrent liabilities. These reclassifications had no effect on the reported results of operations or financial position.</span></div>
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.61
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.65
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2893244 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2893244 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1615772 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1615772 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 operating_segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Use of Estimates</span></div>The Company’s management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates reflected in these condensed consolidated financial statements include but are not limited to, the accrual of research and development expenses, the valuation of stock-based awards, the operating lease right-of-use assets and operating lease liability, and forecasts utilized in management’s going concern assessment.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div>Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and restricted cash. At times, cash balances deposited at major financial banking institutions exceed the federally insured limit. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. The Company has not experienced any losses in such accounts.
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2024Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2024Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2023Q2 angn Number Of Members Of The Board Of Directors
NumberOfMembersOfTheBoardOfDirectors
9 board_member
CY2023Q2 angn Recapitalization Exchange Ratio
RecapitalizationExchangeRatio
0.0181
CY2023Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5375751 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8387025 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8387025 shares
CY2023Q2 angn Cash And Cash Equivalents Acquired Through Reverse Recapitalization
CashAndCashEquivalentsAcquiredThroughReverseRecapitalization
24001000 usd
CY2023Q2 angn Other Current Assets Acquired Through Reverse Recapitalization
OtherCurrentAssetsAcquiredThroughReverseRecapitalization
540000 usd
CY2023Q2 angn Promissory Notes Acquired Through Reverse Recapitalization
PromissoryNotesAcquiredThroughReverseRecapitalization
10027000 usd
CY2023Q2 angn Accrued Liabilities Assumed Through Reverse Recapitalization
AccruedLiabilitiesAssumedThroughReverseRecapitalization
2438000 usd
CY2023Q2 angn Net Assets Acquired Through Reverse Recapitalization
NetAssetsAcquiredThroughReverseRecapitalization
32130000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
600000 usd
CY2023Q2 angn Reverse Recapitalization Transaction Costs
ReverseRecapitalizationTransactionCosts
2900000 usd
angn Reverse Recapitalization Transaction Costs
ReverseRecapitalizationTransactionCosts
2900000 usd
CY2024Q2 angn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1699000 usd
CY2023Q4 angn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1883000 usd
CY2024Q2 angn Advanced Professional Fees
AdvancedProfessionalFees
180000 usd
CY2023Q4 angn Advanced Professional Fees
AdvancedProfessionalFees
300000 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
647000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
376000 usd
CY2024Q2 angn Miscellaneous Receivables
MiscellaneousReceivables
87000 usd
CY2023Q4 angn Miscellaneous Receivables
MiscellaneousReceivables
0 usd
CY2024Q2 angn Other Prepaid Expenses And Other Assets Current
OtherPrepaidExpensesAndOtherAssetsCurrent
255000 usd
CY2023Q4 angn Other Prepaid Expenses And Other Assets Current
OtherPrepaidExpensesAndOtherAssetsCurrent
173000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2868000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2732000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1990000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1948000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1393000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1231000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
597000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
717000 usd
CY2024Q2 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
1600000 usd
CY2023Q4 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
2800000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
812000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
945000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1110000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1849000 usd
CY2024Q2 angn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2379000 usd
CY2023Q4 angn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
912000 usd
CY2024Q2 angn Advanced Payment Of Pre Funded Warrants
AdvancedPaymentOfPreFundedWarrants
1000000 usd
CY2023Q4 angn Advanced Payment Of Pre Funded Warrants
AdvancedPaymentOfPreFundedWarrants
0 usd
CY2024Q2 angn Accrued Other Operating Liabilities Current
AccruedOtherOperatingLiabilitiesCurrent
20000 usd
CY2023Q4 angn Accrued Other Operating Liabilities Current
AccruedOtherOperatingLiabilitiesCurrent
51000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5321000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3757000 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
400000 usd
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
400000 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1305924 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.27
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M4D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2511000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
471934 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.57
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3391 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
95422 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.77
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1679045 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
131000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
755185 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
31.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M24D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
124000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
471934 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.57
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3100000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M15D
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
350000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
279000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
674000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
503000 usd
angn Fair Value Of Common Stock Warrants
FairValueOfCommonStockWarrants
6600000 usd
angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
-600000 usd
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3600000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2300000 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
148764 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
54.19
CY2023Q4 angn Class Of Warrant Or Right Weighted Average Life
ClassOfWarrantOrRightWeightedAverageLife
P5Y6M
angn Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
1032702 shares
angn Class Of Warrant Or Right Weighted Average Exercise Price Issued In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod
0.01
angn Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
0 shares
angn Class Of Warrant Or Right Weighted Average Exercise Price Exercises In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
0
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1181466 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.83
CY2024Q2 angn Class Of Warrant Or Right Weighted Average Life
ClassOfWarrantOrRightWeightedAverageLife
P5Y
CY2024Q2 angn Operating Lease Future Minimum Annual Maintenance Payments Due Remainder Of Fiscal Year
OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueRemainderOfFiscalYear
100000 usd
CY2024Q2 angn Operating Lease Future Minimum Annual Maintenance Payments Due Each Fiscal Year
OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueEachFiscalYear
100000 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
800000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
700000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
765000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
743000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M29D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y5M8D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.079
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
661000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1350000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1383000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1425000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1467000 usd
CY2024Q2 angn Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1765000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8051000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1632000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6419000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
854000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5565000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7229000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7559000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19056000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15586000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11284853 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11284853 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2893244 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2893244 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10779389 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10779389 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1615772 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1615772 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.61
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.77
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
904297 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1434021 shares
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001601485-24-000045-index-headers.html Edgar Link pending
0001601485-24-000045-index.html Edgar Link pending
0001601485-24-000045.txt Edgar Link pending
0001601485-24-000045-xbrl.zip Edgar Link pending
angn-20240630.htm Edgar Link pending
angn-20240630.xsd Edgar Link pending
angn-20240630_cal.xml Edgar Link unprocessable
angn-20240630_def.xml Edgar Link unprocessable
angn-20240630_lab.xml Edgar Link unprocessable
angn-20240630_htm.xml Edgar Link completed
angn-20240630_pre.xml Edgar Link unprocessable
ex311_eltx-06302024x10xq.htm Edgar Link pending
ex312_eltx-06302024x10xq.htm Edgar Link pending
ex321eltx-06302024x10xq.htm Edgar Link pending
ex322_eltx-06302024x10xq.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending